Folinic Acid and Vascular Reactivity in HIV
Human Immunodeficiency Virus (HIV) Infection
About this trial
This is an interventional prevention trial for Human Immunodeficiency Virus (HIV) Infection focused on measuring folic acid; folates; Vascular Reactivity; HIV
Eligibility Criteria
Inclusion Criteria:
- individual known HIV disease
- aged 18 or over
- on ART for at least 6 months
- undetectable viral load (less than 50 copies/ml)
- CD4 counts more than 200 cells/mm3.
Exclusion Criteria:
- diabetes mellitus
- any active infection
- liver disease
- renal disease
- history of cardiovascular disease
- uncontrolled hypertension
- pregnancy
- use of illicit drug
- mental illness
- use of tobacco
- taking any dietary supplement (such as folic acid or antioxidants)
- women taking hormone replacement therapy
Sites / Locations
- Hospital de Clínicas de Porto Alegre
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Folinic Acid
Placebo
Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.